In fact, a recent publication (Ogino et al. 2005) describes evidence for the interactions of CDKN1A/p21 and p53 in conferring resistance to chemotherapy combined with gefitinib in colon cancer patients. The gene discussed is CDKN1A; the disease is malignant colon neoplasm.